Study of SNX-5422 in TP53 Null Cancers
NCT02612285
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class
Stopped
Recruitment very slow - study could not be enrolled
Conditions
Cancer
Interventions
DRUG:
SNX-5422
Sponsor
Esanex Inc.